Blogs

How are Pharma CEO's Like the Ostrich?

How Far We've Come: Radio Program Looks at Roots of PAT/QbD

Complacent or Overly Compliant? Why Has Industry Been Slow to Adopt Single-Use for Bioprocess Control?

PAT Won't Be Mandated (But Don't Look for Any New Incentives Either): CDER Deputy Director Webber

"Ajaz the Avenger" on the Need for Unity: For PAT and QbD, Pharma Must Learn from Bioprocessing

Ali Afnan to Leave FDA

Ranbaxy, Wishful Thinking and the Fudge Factor